Regeneron Pharmaceuticals, Inc.
REGN
$828.50
-$5.54-0.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 19.31% | -5.80% | |||
| Total Other Revenue | 12.91% | -28.25% | |||
| Total Revenue | 19.01% | -7.18% | |||
| Cost of Revenue | -0.22% | 0.10% | |||
| Gross Profit | 49.56% | -16.80% | |||
| SG&A Expenses | 2.22% | -16.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.34% | -4.19% | |||
| Operating Income | 90.72% | -17.12% | |||
| Income Before Tax | 83.81% | -20.36% | |||
| Income Tax Expenses | 122.02% | -47.76% | |||
| Earnings from Continuing Operations | 78.34% | -13.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 78.34% | -13.90% | |||
| EBIT | 90.72% | -17.12% | |||
| EBITDA | 77.90% | -16.83% | |||
| EPS Basic | 80.42% | -14.81% | |||
| Normalized Basic EPS | 77.46% | -55.97% | |||
| EPS Diluted | 81.19% | -14.09% | |||
| Normalized Diluted EPS | 78.22% | -55.58% | |||
| Average Basic Shares Outstanding | -1.15% | 1.07% | |||
| Average Diluted Shares Outstanding | -1.58% | 0.19% | |||
| Dividend Per Share | 0.00% | 6.82% | |||
| Payout Ratio | -0.45% | 0.23% | |||